Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first ...

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The ...

JERUSALEM, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, ...

An update from Alpha Tau Medical Ltd ( ($DRTS) ) is now available. On January 6, 2026, Alpha Tau Medical reported final results from its ...

An update from Alpha Tau Medical Ltd ( ($DRTS) ) is now available. On January 5, 2026, Alpha Tau Medical announced it has submitted the first ...

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, announced today that the FDA ...

Alpha Tau Medical’s proprietary Alpha DaRT device safely delivers alpha radiation with localized precision to treat cancers. Alpha Tau is waiting for FDA feedback to initiate a US pivotal trial in ...

Radioactive decay produces three flavors of emissions: alpha, beta, and gamma. Alpha particles comprise 2 neutrons and 2 protons. Because of their large mass and relatively slow speed, alpha particles ...